OTCMKTS:FSNUY Fresenius SE & Co. KGaA (FSNUY) Stock Price, News & Analysis $11.11 -0.08 (-0.70%) As of 04/17/2025 03:51 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort InterestBuy This Stock About Fresenius SE & Co. KGaA Stock (OTCMKTS:FSNUY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FSNUY alerts:Sign Up Key Stats Today's Range$11.07▼$11.3550-Day Range$9.58▼$11.1952-Week Range$7.11▼$11.35Volume33,745 shsAverage Volume62,994 shsMarket Capitalization$24.82 billionP/E Ratio52.90Dividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewFresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.Read More… Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter. Email Address FSNUY Stock News HeadlinesFresenius Medical Care (ETR:FME) Is Paying Out A Larger Dividend Than Last YearApril 9, 2025 | finance.yahoo.comFresenius: Turnaround For Company, Stock PriceMarch 16, 2025 | seekingalpha.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 18, 2025 | American Alternative (Ad)Fresenius Raises €1.1 Billion for Stake in Dialysis CompanyMarch 4, 2025 | finance.yahoo.comFresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)March 3, 2025 | finance.yahoo.comFresenius Seeks €1.1 Billion for Stake in Dialysis CompanyMarch 3, 2025 | bloomberg.comFresenius SE & Co. KGaA (0OO9) Gets a Hold from Goldman SachsFebruary 26, 2025 | markets.businessinsider.comFresenius Sees Hospital Costs Holding Back Higher Profit in 2025February 26, 2025 | financialpost.comSee More Headlines FSNUY Stock Analysis - Frequently Asked Questions How have FSNUY shares performed this year? Fresenius SE & Co. KGaA's stock was trading at $8.75 on January 1st, 2025. Since then, FSNUY shares have increased by 27.0% and is now trading at $11.11. View the best growth stocks for 2025 here. How were Fresenius SE & Co. KGaA's earnings last quarter? Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) released its earnings results on Wednesday, February, 26th. The company reported $0.18 earnings per share for the quarter. The company had revenue of $6.01 billion for the quarter. How do I buy shares of Fresenius SE & Co. KGaA? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2025Today4/18/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:FSNUY CIKN/A Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees193,865Year Founded1912Profitability EPS (Most Recent Fiscal Year)$0.21 Trailing P/E Ratio52.90 Forward P/E Ratio14.06 P/E GrowthN/ANet Income$382.05 million Net MarginsN/A Pretax Margin3.84% Return on Equity3.72% Return on Assets1.67% Debt Debt-to-Equity Ratio0.57 Current Ratio1.36 Quick Ratio1.05 Sales & Book Value Annual Sales$24.01 billion Price / Sales1.03 Cash Flow$1.66 per share Price / Cash Flow6.68 Book Value$9.52 per share Price / Book1.17Miscellaneous Outstanding Shares2,234,010,000Free FloatN/AMarket Cap$24.82 billion OptionableNot Optionable Beta0.86 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:FSNUY) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Fresenius SE & Co. KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.